Q-omics provides the consensus-scored G6PC3 profile across patient tissues and cancer cell-line models. G6PC3 expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in UCEC. Among the 18 cancer types available for tumor–normal comparison, G6PC3 is differentially expressed in 17, with the highest sampling consensus in KIRP. Additionally, G6PC3 RNA expression shows 19,395 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UCEC, KIRP, and ACC as cancer lineages where G6PC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for G6PC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes G6PC3 survival associations across molecular data types. G6PC3 RNA expression shows survival associations in the most cancer types (28), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible G6PC3 RNA expression–survival associations across cancer types. High G6PC3 expression shows unfavorable associations in UVM, LIHC, KIRC and KIRP, but favorable associations in UCEC and BRCA. The UCEC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UCEC as the clearest survival context for G6PC3 RNA expression.
This table summarizes G6PC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRP for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for G6PC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. G6PC3 shows lower tumor expression in KICH and higher tumor expression in KIRP, COAD, LIHC, STAD and BLCA. The KIRP box plot shows higher G6PC3 RNA expression in tumor versus normal tissue (log2 FC = +1.292, t-test p < 0.001).
This table shows molecular features associated with G6PC3 in patient tissues and cancer cell lines. In patient samples, G6PC3 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, G6PC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in CNS and SKIN.
